<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03017885</url>
  </required_header>
  <id_info>
    <org_study_id>1199-0272</org_study_id>
    <nct_id>NCT03017885</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy</brief_title>
  <official_title>An Active Surveillance to Monitor the Real World Safety in Indian Patients Prescribed Nintedanib for the Treatment of Locally Advanced, Metastatic or Locally Recurrent Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Tumor Histology After First Line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This active surveillance aims to collect the safety data of 100 NSCLC patients treated with
      nintedanib per the approved Indian label within 2 years from the date of commercial
      availability of the drug in India (23rd January 2017). The objective is to look at the safety
      of nintedanib in the real world setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2017</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of all Adverse Drug Reactions (ADRs) in nintedanib &amp; docetaxel treated patients</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of all Serious Adverse Events (SAEs) in nintedanib &amp; docetaxel treated patients</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who require nintedanib dose reductions and discontinuations due to adverse events.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Patients who started treatment with nintedanib &amp; docetaxel after 23rd January, 2017 and have discontinued the drug at the time of participation in the active surveillance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Patients who started treatment with nintedanib &amp; docetaxel after 23rd January, 2017 and are continuing the drug at the time of participation in the active surveillance .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <description>Patients who have been newly prescribed nintedanib &amp; docetaxel at the time of participation in the active surveillance.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        This active surveillance aims to collect the safety data of 100 NSCLC patients treated with
        nintedanib per the approved Indian label within 2 years from the date of commercial
        availability of the drug in India (23rd January 2017).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients â‰¥18 years of age with locally advanced and/or metastatic NSCLC of stage IIIB
             or IV, or recurrent NSCLC and adenocarcinoma histology after first line chemotherapy
             who have initiated or will initiate nintedanib &amp; docetaxel according to the package
             insert after the commercial availability of drug in India (23rd January 2017).

          -  Patients in whom it is possible to obtain voluntary informed consent from either the
             patient or patient's legally authorised representative (applicable for Group B and C
             patients).

          -  Patients in whom data collection is possible from the medical records (applicable for
             Group A and B patients).

          -  Further inclusion criteria apply.

        Exclusion Criteria:

          -  Patients who were previously treated with nintedanib.

          -  Patients who are positive for endothelial growth factor receptor (EGFR) mutations or
             anaplastic lymphoma kinase (ALK) rearrangements

          -  Patients who are participating in a clinical trial.

          -  Further exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Narayana Hrudyalaya</name>
      <address>
        <city>Bangalore</city>
        <zip>560099</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pragya Coca</last_name>
      <phone>080 71 222 222</phone>
      <email>pragnya.coca.dr@narayanahealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manipal Hospitals</name>
      <address>
        <city>Bengaluru</city>
        <zip>560017</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Poonam Patil</last_name>
      <phone>+91 9945687185</phone>
      <email>poonampatil@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HCG Hospital</name>
      <address>
        <city>Bengaluru</city>
        <zip>560027</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shekar Patil</last_name>
      <phone>080 40206000</phone>
      <email>spassociates6@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sparsh Hospitals and Critical Care</name>
      <address>
        <city>Bhubaneshwar</city>
        <zip>751007</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghanshyam Biswas</last_name>
      <phone>91-9937500878</phone>
      <email>drgbiswas@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Apollo Health City Hospital</name>
      <address>
        <city>Hyderabad</city>
        <zip>500033</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vamshi Krishna</last_name>
      <phone>+91 9959778112</phone>
      <email>drmvkrishnaonco@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Basavatarakam Indo - American Cancer Hospital &amp; Research Ins</name>
      <address>
        <city>Hyderabad</city>
        <zip>500034</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Senthil Rajappa</last_name>
      <phone>+91-40-23551235</phone>
      <email>senthiljrajappa@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yashoda Hospitals</name>
      <address>
        <city>Hyderabad</city>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikhil Ghadyalpatil</last_name>
      <phone>+91-40-67779999</phone>
      <email>nikhilghadyalpatil@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chittaranjan National Cancer Institute</name>
      <address>
        <city>Kolkata</city>
        <zip>700026</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Indranil Ghosh</last_name>
      <phone>+91-9163223215</phone>
      <email>dr.indraghosh@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kasturba Medical College and Hospital</name>
      <address>
        <city>Mangalore</city>
        <zip>575001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sourjya Banerjee</last_name>
      <phone>+919880345339</phone>
      <email>sourjya.banerjee@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 10, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2017</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

